Kraig Biocraft Laboratories, Inc.

KBLB

US50075W1045

Specialty Chemicals

Delayed OTC Markets Other stock markets 11:41:40 2024-04-30 am EDT			5-day change	1st Jan Change
0.0899 ^USD	-0.24%		-9.01%	+132.30%

Apr. 29	Kraig Biocraft Laboratories, Inc. Reports Signing Agreements in South East Asia	CI
Apr. 22	Kraig Biocraft Laboratories, Inc. Successfully Completes Recombinant Cocoon Production from Spring Trials	CI

Kraig Biocraft Laboratories, Inc. announced that it has received $8 million in funding from Yorkville Advisors Global LP

November 14, 2022

Kraig Biocraft Laboratories, Inc. that it has received $8,000,000 in a round of funding on November 15, 2022. The company has issued convertible debt in the transaction. The transaction includes participation from existing investor, Yorkville Advisors Global LP.

Latest news about Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. Reports Signing Agreements in South East Asia	Apr. 29	CI
Kraig Biocraft Laboratories, Inc. Successfully Completes Recombinant Cocoon Production from Spring Trials	Apr. 22	CI
Kraig Biocraft Laboratories Signs Agreement in Vietnam's Silk Production Capital	Apr. 08	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 01	CI
Kraig Biocraft Laboratories, Inc. Provides Update on Launch of Spring Trials	Mar. 12	CI
Kraig Biocraft Laboratories, Inc. Announces New Premium Spider Silk and Pima Cotton Composite Yarn	Feb. 20	CI
Kraig Biocraft Laboratories, Inc. Announces New Spider Silk Production Facility in Vietnam's Silk Capital	Feb. 13	CI
Kraig Biocraft Laboratories, Inc. Announces the Successful Creation of A New Recombinant Spider Silk Hybrid	Feb. 06	CI
Kraig Biocraft Laboratories, Inc. Announces Early Start to Production Season with Successful Small Batch Delivery of Spider Silk	Dec. 14	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Kraig Biocraft Laboratories, Inc. Auditor Raises 'Going Concern' Doubt	23-03-28	CI
Kraig Biocraft Laboratories Delivers the First Two Hybrid Dragon Silk™ Silkworm Strains for Commercial Production	23-01-26	CI
Kraig Biocraft Laboratories, Inc. announced that it has received $8 million in funding from Yorkville Advisors Global LP	22-11-14	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Kraig Biocraft Laboratories Expands Operational Footprint in Vietnam	22-08-17	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-01	CI
Kraig Biocraft Laboratories Introduces New, Enhanced Line of Dragon Silk™ Silkworms for Commercial Production	22-07-06	CI
Kraig Biocraft Laboratories, Inc. in Collaboration with Its Joint Venture Partner, Kings Group, the Company Has Selected A High-Quality Garment Manufacturer to Produce Spydasilk's(Tm) First Apparel Line	22-06-27	CI
Kraig Biocraft Laboratories Subcontractor Pilot Production Has Achieved Required Spider Silk Production Levels for the Spydasilk™ Apparel Launch	22-06-21	CI
Kraig Biocraft Laboratories, Inc. Enters Biomedical Field with First Sample Shipments of Fibers and Fabrics for Tissue Engineering	22-05-17	CI
Kraig Biocraft Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-06	CI
Kraig Biocraft Laboratories Updates on Spider Silk Production	22-04-27	CI

Chart Kraig Biocraft Laboratories, Inc.

Duration

Period

More charts

Company Profile

Kraig Biocraft Laboratories, Inc. develops fibers using recombinant deoxyribonucleic acid (DNA) technology for commercial applications in technical textiles. The Company uses genetically engineered silkworms that produce spider silk proteins to create its recombinant spider silk. Its primary fiber technology includes natural and engineered variants of spider silk produced from domesticated mulberry silkworms. The Companyâs products use the characteristics of spider silk, specifically dragline silk from Nephila clavipes and variants thereof. Its recombinant spider silk fiber blends the silk proteins found in spider silk with the native silkworm silk proteins. Its products include Monster Silk, Dragon Silk, and other products. Its applications include performance apparel, workwear, filtration, luxury fashion, flexible composites, medical implants, cosmetics and more. The Company also focuses on developing various recombinant silks and other protein-based fibers and materials.

Sector

Specialty Chemicals

More about the company

Income Statement Evolution

More financial data

Sector Other Specialty Chemicals

	1st Jan change	Capi.
KRAIG BIOCRAFT LABORATORIES, INC.	+132.30%	93.58M
ECOLAB INC.	+15.35%	63.38B
SIKA AG	-3.80%	46.51B
GIVAUDAN SA	+13.26%	39.91B
FUJIFILM HOLDINGS CORPORATION	+19.57%	25.57B
EMS-CHEMIE HOLDING AG	+8.22%	18.95B
CELANESE CORPORATION	-0.01%	17.58B
POSCO FUTURE M CO., LTD.	-21.03%	16.1B
SYMRISE AG	+1.06%	14.98B
ALBEMARLE CORPORATION	-16.55%	14.78B